Cell therapy weekly: US FDA-approved Phase II mesenchymal stem cell therapy for Parkinson’s disease launched

Written by RegMedNet

This week: a Phase II clinical trial has been launched to assess mesenchymal adult stem cells as a disease-modifying therapy for Parkinson’s disease; Agenus (MA, USA) has announced the dosing of the first cancer patient with agenT-797, an allogeneic iNKT cell therapy, in a Phase I clinical trial; and TreeFrog Therapeutics (Bordeaux, France) has reported the production of a single batch of 15 billion iPSCs in a 10L bioreactor with exponential amplification of 276-fold per week. The news highlights: US FDA-approved Phase II mesenchymal stem cell therapy for Parkinson’s disease launched First cancer patient dosed with iNKT cell therapy, Agenus...

To view this content, please register now for access

It's completely free